報價延遲最少15分鐘:2024/12/23 22:23 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.43 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.89/-2.25
|
|
企業價值
1.10B
|
| 資產負債 |
|
每股賬面淨值
5.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:23 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |